دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Functional coronary angiography in symptomatic patients with no obstructive coronary artery disease
Sonali Kumar MD,Puja K. Mehta MD,Parham Eshtehardi MD,Olivia Y. Hung MD,Jin-Sin Koh MD,Arnav Kumar MD, MSCR,Ahmed Al-Badri MD,Rani Rabah MD,Melroy D'Souza MD,Sonu Gupta MBBS,Michael McDaniel MD,Viola Vaccarino MD PhD,John Douglas MD,Kreton Mavromatis MD,Joo Myung Lee MD MPH PhD,Arshed Quyyumi MD,Habib Samady MD, FACC
doi : 10.1002/ccd.29237
Volume 98, Issue 5 p. 827-835
Patients without obstructive coronary artery disease (CAD) may have epicardial or microvascular dysfunction. The purpose of this study was to characterize patterns of epicardial and microvascular dysfunction in men and women with stable and unstable angina undergoing functional coronary angiography to inform medical therapy.
Functional coronary angiography for coronary microvascular function: the time has come!
Odayme Quesada MD,Timothy D. Henry MD
doi : 10.1002/ccd.29971
Volume 98, Issue 5 p. 836-837
Relationship between predicting bleeding complication in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score and mortality among patients with atrial fibrillation undergoing percutaneous coronary intervention
Anum Asif MD,Ahmet Sezer PhD,Floyd Thoma BS,Catalin Toma MD,John Schindler MD,Jeffrey Fowler MD,Conrad Smith MD,Oscar C. Marroquin MD,Suresh R. Mulukutla MD
doi : 10.1002/ccd.29399
Volume 98, Issue 5 p. 838-845
The predicting bleeding complication in patients undergoing stent implantation and subsequent dual antiplatelet therapy, PRECISE-DAPT (P-DAPT) score has been validated in large cohorts as an effective tool in predicting bleeding complication after dual antiplatelet therapy (DAPT) as well as in predicting in-hospital mortality. The implication of using this score to predict outcomes, including mortality in patients with atrial fibrillation (AF) undergoing PCI is unknown.
PRECISE-DAPT: A tool to measure if Afib patients may risk being stretched too thin
Francois P. Kaleta DO,Ian C. Gilchrist MD, MSCAI
doi : 10.1002/ccd.29966
Volume 98, Issue 5 p. 846-847
Individual patient data analysis of the BIOFLOW study program comparing safety and efficacy of a bioresorbable polymer sirolimus eluting stent to a durable polymer everolimus eluting stent
Ralph Toelg MD,Ton Slagboom MD,Johannes Waltenberger MD,Thierry Lefèvre MD,Shigeru Saito MD,David E. Kandzari MD,Jacques Koolen MD,Gert Richardt MD
doi : 10.1002/ccd.29254
Volume 98, Issue 5 p. 848-856
This analysis of pooled individual patient data (IPD) aimed to evaluate the safety and efficacy of a bioresorbable polymer sirolimus eluting stent system (BP-SES; Orsiro) compared to a durable polymer everolimus eluting stent system (DP-EES; Xience) in the pooled population as well as in subgroups.
Angiographic performance of everolimus-eluting stents for the treatment of coronary in-stent restenosis in daily practice
Jens Wiebe MD,Himanshu Rai PhD,Constantin Kuna MD,Salvatore Cassese MD PhD,Thorsten Kessler MD,Tobias Rheude MD,Roisin Colleran MB BCh,Heribert Schunkert MD,Tobias Koch MD,Sebastian Kufner MD,Michael Joner MD,Adnan Kastrati MD,Robert A. Byrne MB BCh PhD
doi : 10.1002/ccd.29225
Volume 98, Issue 5 p. 857-862
The present study aims to analyze the angiographic anti-restenotic performance of durable polymer everolimus-eluting stents (EES) for the treatment of in-stent restenosis (ISR) in daily practice.
Auf wiedersehen coronary stenosis? Not so fast mein Herr
Omar Wani MD, FSCAI,Samuel M. Butman MD, FSCAI
doi : 10.1002/ccd.29968
Volume 98, Issue 5 p. 863-863
Usefulness of oral anticoagulation in patients with coronary aneurysms: Insights from the CAAR registry
Fabrizio D'Ascenzo MD, PhD,Andrea Saglietto MD,Harish Ramakrishna MD, PhD,Alessandro Andreis MD,Jesús M. Jiménez-Mazuecos MD, PhD,Luis Nombela-Franco MD,Enrico Cerrato MD,Christoph Liebetrau MD, PhD,Emilio Alfonso-Rodríguez MD,Rodrigo Bagur MD, PhD,Mohamad Alkhouli MD, PhD,Gaetano M. De Ferrari MD, PhD,Iván J. Núñez-Gil MD, PhD,The CAAR Investigators
doi : 10.1002/ccd.29243
Volume 98, Issue 5 p. 864-871
To assess the Usefulness of oral anticoagulation therapy (OAT) in patients with coronary artery aneurysm (CAA).
Oral anticoagulants for coronary artery aneurysm: For few or for all?
Ankush Gupta MD, DM,Ashok Seth FRCP, MSCAI, FACC, FESC, FAPSIC, DSc
doi : 10.1002/ccd.29979
Volume 98, Issue 5 p. 872-873
Use and outcomes of the PK Papyrus covered stent in France: SOS PK Papyrus Registry
Marco Hernández-Enríquez MD, PhD,Loic Belle MD,Hende Madiot RN,Michel Pansieri MD,Geraud Souteyrand MD, PhD,Fabiel de Poli MD,Christophe Piot MD, PhD,Ziad Boueri MD,Edouard Gerbaud MD, PhD,Emmanuel Boiffard MD,Hakim Benamer MD,Benoit Lattuca MD, PhD,Philippe Commeau MD,Richard Gervasoni MD,Gregoire Rangé MD,Nicolas Lhoest MD,Stéphanie Marliere MD,Mohamed Abdellaoui MD,Nicolas Delarche MD,Gilles Zemour MD,Jean Armengaud MD,Max Carre MD,Sebastien Levesque MD,Nicolas Boudou MD
doi : 10.1002/ccd.29328
Volume 98, Issue 5 p. 874-881
To evaluate the rate of procedural success and long-term outcomes of the PK Papyrus (PKP) covered stent (CS).
Covered stents: Initially life-saving but long-term consequences persist
Cindy L. Grines MD, MSCAI,Pradyumna E. Tummala MD, FSCAI
doi : 10.1002/ccd.29980
Volume 98, Issue 5 p. 882-883
Outcomes of rotational atherectomy versus orbital atherectomy for the treatment of heavily calcified coronary stenosis: A systematic review and meta-analysis
Abdul Ahad Khan MD,Ghulam Murtaza MD,Muhammad Faisal Khalid MD,Christopher J. White MD,Mamas A. Mamas MD,Debabrata Mukherjee MD, MS,Hani Jneid MD,Madhan Shanmugasundaram MD,Harsha S. Nagarajarao MD,Timir K. Paul MD, PhD
doi : 10.1002/ccd.29430
Volume 98, Issue 5 p. 884-892
The optimal approach to deal with severe coronary artery calcification (CAC) during percutaneous coronary intervention (PCI) remains ill-defined.
The dinosaur that still roars
James C. Blankenship MD, MHCM, MSCAI
doi : 10.1002/ccd.29969
Volume 98, Issue 5 p. 893-894
Dose-reducing fluoroscopic system decreases patient but not occupational radiation exposure in chronic total occlusion intervention
Pablo Salinas MD, PhD,Roberto M. Sanchez-Casanueva MSc, PhD,Nieves Gonzalo MD, PhD,Jorge A. Gil MD,Carlos H Salazar MD,Pilar Jimenez-Quevedo MD, PhD,Luis Nombela-Franco MD, PhD,Ivan J. Nuñez-Gil MD, PhD,Hernan Mejia-Renteria MD,Jose M. Fernandez-Soto MSc, PhD,Antonio Fernandez-Ortiz MD, PhD,Eliseo Vaño MSc, PhD,Javier Escaned MD, PhD
doi : 10.1002/ccd.29253
Volume 98, Issue 5 p. 895-902
Several novel low-dose fluoroscopic systems (LDS) developed recently, but real practice information of the net benefit for the patient and professionals is scarce. We evaluated separately patient and operator radiation exposure during percutaneous interventions of chronic total occlusions (CTO).
Radiation diligence must continue when using newer fluoroscopes
Stephen Balter PhD
doi : 10.1002/ccd.29964
Volume 98, Issue 5 p. 903-903
Hot topics in interventional cardiology: Proceedings from the society for cardiovascular angiography and interventions (SCAI) 2021 think tank
Srihari S. Naidu MD, FAHA, FSCAI,Suzanne J. Baron MD, FSCAI,Marvin H. Eng MD, FSCAI,Shyam K. Sathanandam MD, FSCAI,David A. Zidar MD, PhD, FSCAI,Dmitriy N. Feldman MD, FSCAI,Frank F. Ing MD, MSCAI,Faisal Latif MD, FSCAI,Michael J. Lim MD, FSCAI,Timothy D. Henry MD, MSCAI,Sunil V. Rao MD, FSCAI,George D. Dangas MD, PHD, MSCAI,James B. Hermiller MD, MSCAI,Ramesh Daggubati MD, FSCAI,Binita Shah MD, FSCAI,Lawrence Ang MD, FSCAI,Herbert D. Aronow MD, FSCAI,Subhash Banerjee MD, FSCAI,Lyndon C. Box MD, FSCAI,Ronald P. Caputo MD, FSCAI,Mauricio G. Cohen MD, FSCAI,Megan Coylewright MD, FSCAI,Peter L. Duffy MD, MMM, FSCAI,Andrew M. Goldsweig MD, FSCAI,Donald J. Hagler MD, MSCAI,Beau M. Hawkins MD, FSCAI,Ziyad M. Hijazi MD, MPH, MSCAI,Sasanka Jayasuriya MD, FSCAI,Henri Justino MD, FSCAI,Andrew J. Klein MD, FSCAI,Chad Kliger MD, FSCAI,Jun Li MD, FSCAI,Ehtisham Mahmud MD, FSCAI,John C. Messenger MD, FSCAI,Brian H. Morray MD,Sahil A. Parikh MD, FSCAI,John Reilly MD, FSCAI,Eric Secemsky MD, FSCAI,Mehdi H. Shishehbor MD, FSCAI,Molly Szerlip MD, FSCAI,Steven J. Yakubov MD, MSCAI,Cindy L. Grines MD, MSCAI,And the members of the SCAI 2020 Think Tank Consortium: Lindsay Ackman,Jennifer Alvarez-Breckenridge,Colleen Baird,David Baker,Charles Berry,Manisha Bhattacharya,Seth Bilazarian MD,Rosanne Bowen,Kevin Brounstein,Cole Cameron,Rafael Cavalcante,Casey Culbertson,Pedro Diaz,Susan Emanuele,Erin Evans,Rob Fletcher,Tina Fortune,Priya Gaiha MD,Devi Govender,Dan Gutfinger,Kurt Haggstrom,Andrea Herzog,Denise Hite,Bethany Kalich,Ann Kirkland,Toni Kohler,Holly Laurisden,Kevin Livolsi,Lois Lombardi,Sarah Lowe,Kevin Marhenke,Joie Meikle,Neil Moat MD,Megan Mueller,Roberto Patarca,Jeff Popma MD,Novena Rangwala,Chuck Simonton MD,Jerry Stokes,Margaret Taber,Christopher Tieche,John Venditto MD, MBA,Nick E. J. West MD,Laurie Zinn
doi : 10.1002/ccd.29898
Volume 98, Issue 5 p. 904-913
The Society for Cardiovascular Angiography and Interventions (SCAI) Think Tank is a collaborative venture that brings together interventional cardiologists, administrative partners, and select members of the cardiovascular industry community annually for high-level field-wide discussions. The 2021 Think Tank was organized into four parallel sessions reflective of the field of interventional cardiology: (a) coronary intervention, (b) endovascular medicine, (c) structural heart disease, and (d) congenital heart disease. Each session was moderated by a senior content expert and co-moderated by a member of SCAI's Emerging Leader Mentorship program. This document presents the proceedings to the wider cardiovascular community in order to enhance participation in this discussion, create additional dialog from a broader base, and thereby aid SCAI, the industry community and external stakeholders in developing specific action items to move these areas forward.
Nanospheres encapsulated everolimus delivery into arterial wall–the tissue pharmacokinetics and vascular response experimental study
Krzysztof Milewski MD, PhD,Anna Bry?a-Wojciechowska MS,Piotr P. Buszman MD, PhD,Katarzyna Jelonek MS, PhD,Mateusz Kachel MD,Pawe? G?sior MD, PhD,Agata Krauze MS, PhD,Aleksandra B?achut MD,Monika Musia?-Kulik MS, PhD,Armando Tellez MD,Serge D. Rousselle DVM,R. Stefan Kiesz MD, PhD,Janusz Kasperczyk MS, PhD,Pawe? E. Buszman MD, PhD
doi : 10.1002/ccd.29258
Volume 98, Issue 5 p. 914-922
This study aimed to evaluate the pharmacokinetic profile and tissue effects of everolimus delivered into arterial wall using biodegradable nanospheres.
Bilateral branch pulmonary artery Pulsta valve implantation for treatment of large right ventricular outflow tract in a high-risk patient
Jung Yoon Kim MD,Seong-Ho Kim MD, PhD,So Ick Jang MD
doi : 10.1002/ccd.29857
Volume 98, Issue 5 p. 923-927
Percutaneous pulmonary valve implantation (PPVI) has been implemented as a novel alternative strategy to surgical pulmonary valve replacement. However, PPVI has an inevitable limitation: the large right ventricular outflow tract (RVOT) lesions exhibit variable geometry and significant pulmonary regurgitation (PR). To overcome this limitation, bilateral branch pulmonary artery (PA) valve implantations using Melody or Sapien valves have been attempted and have shown a reduction in right ventricular volume with clinical benefits in the intermediate term. Nevertheless, these trials also have constraints of large branch PA size. Recently, a feasibility study using the Pulsta valve (Tae Woong Medical Co, Gyeonggi-do, South Korea) for native RVOTs was reported; the diameter of the Pulsta valve ranges from 18 to 32?mm. Herein, we present a successful percutaneous bilateral branch PA valve implantation using two 32?mm Pulsta valves in a 59-year-old man who showed right heart failure with severe pulmonary regurgitation despite several open heart surgeries for tetralogy of Fallot. The main PA was measured to be 49?mm, and both the right and left PAs were measured to be 30?mm.
Clinical outcomes of endovascular procedure using VIABAHN® VBX covered stent in complex aortoiliac artery disease: Result from AVOCADO study
Masahiko Fujihara MD,Mitsuyoshi Takahara MD, PhD,Terutoshi Yamaoka MD, PhD,Osamu Iida MD,Tai Kojima MD,Kazuki Tobita MD,Tatsuya Nakama MD,Ryoichi Kyuragi MD, PhD,Shigeo Ichihashi MD, PhD,Yoshimitsu Soga MD, PhD
doi : 10.1002/ccd.29920
Volume 98, Issue 5 p. 928-937
To investigate the safety and efficacy of a balloon-expandable covered stent in the treatment of complex aortoiliac artery disease.
Covered stents favored in complex aortoiliac disease
John G. Winscott MD,William B. Hillegass MD, PhD
doi : 10.1002/ccd.29965
Volume 98, Issue 5 p. 938-939
Meta-analysis comparing valve-in-valve TAVR and redo-SAVR in patients with degenerated bioprosthetic aortic valve
Sameer Saleem MD,Waqas Ullah MD,Mubbasher Ameer Syed MD,Michael Megaly MD,Nishanth Thalambedu MD,Sundas Younas MBBS,Salman Zahid MD … See all authors
doi : 10.1002/ccd.29789
Volume 98, Issue 5 p. 940-947
The comparative efficacy and safety of valve-in-valve transcatheter aortic valve replacement (ViV-TAVR) and redo-surgical AVR (redo-SAVR) in patients with degenerated bioprosthetic aortic valves remain unknown.
Valve-in-valve transcatheter aortic valve replacement versus re-do surgical aortic valve replacement: A call for randomized controlled trials
John P. Reilly MD,Puja B. Parikh MD, MPH
doi : 10.1002/ccd.29970
Volume 98, Issue 5 p. 948-949
The need for future coronary access following surgical or transcatheter aortic valve replacement
James B. Hermiller Jr MD,Candace L. Gunnarsson EdD,Michael P. Ryan MS,Kimberly A. Moore Pharm D, MS,Seth J. Clancy MPH,William Irish PhD
doi : 10.1002/ccd.29841
Volume 98, Issue 5 p. 950-956
The aim of the study was to estimate the percentage of Medicare patients needing coronary access for percutaneous coronary intervention (PCI) or coronary angiography following aortic valve replacement (AVR). Indications for TAVR have expanded to include younger and low-risk patients, raising the question of coronary access for future procedures. Medicare patients <80?years old with an AVR between 2011 and 2018 were included. Time-to-event analyses were conducted using Cox hazard models to estimate risk of coronary access up to 7?years after AVR. Model adjustments included age, sex, race, region, comorbidity, concomitant CABG, and smoking. A total of 13,469 Medicare patients (mean age 70.6) met inclusion criteria. Models estimated that 2.5% of patients at 1-year post-index and 17% at over 7?years would need coronary access. For patients who had SAVR (with or without CABG), estimates for coronary access were similar and over 15% after 6.5?years. For TAVR patients, with a previous PCI, 28% at 4.5?years required coronary access, which was higher than TAVR patients without a previous PCI. SAVR patients with and without CAD at baseline were similar; however, TAVR patients with CAD had a 22% rate of coronary access versus 7% for those without at 3?years. Approximately half of patients who needed coronary access returned to the same hospital as their initial AVR. Coronary access is required in a substantial portion of AVR patients especially those with PCI or a history of CAD undergoing TAVR. The need for coronary access may increase as transcatheter AVR becomes accessible to younger patients with a longer life expectancy.
Coronary artery access after aortic valve intervention
Rodrigo Bagur MD, PhD, FRCPC, FAHA,Hani Jneid MD, FACC, FAHA, FSCAI
doi : 10.1002/ccd.29982
Volume 98, Issue 5 p. 957-958
Use and outcomes of cerebral embolic protection for transcatheter aortic valve replacement: A US nationwide study
Muhammad Zia Khan MD, MS,Salman Zahid MD,Muhammad U. Khan MD,Asim Kichloo MD,Waqas Ullah MD,Yasar Sattar MD,Muhammad Bilal Munir MD,Atul Singla MD,Andrew M. Goldsweig MD, MS,Sudarshan Balla MD
doi : 10.1002/ccd.29842
Volume 98, Issue 5 p. 959-968
Outcomes data on the use of cerebral embolic protection devices (CPDs) with transcatheter aortic valve replacement (TAVR) remain limited. Previous randomized trials were underpowered for primary outcomes of stroke prevention and mortality.
An interventional approach to left ventricular assist device outflow graft obstruction
Zachary M. Gertz MD,Cory R. Trankle MD,John D. Grizzard MD,Mohammed A. Quader MD,Benjamin Medalion MD,Kendall E. Parris RT,Keyur B. Shah MD
doi : 10.1002/ccd.29556
Volume 98, Issue 5 p. 969-974
LVADs provide life-sustaining treatment for patients with heart failure, but their complexity allows for complications. One complication, LVAD outflow graft obstruction, may be misdiagnosed as intraluminal thrombus, when more often it is extraluminal compression from biodebris accumulation. It can often be treated endovascularly with stenting. This case series describes diagnostic and procedural techniques for the treatment of left ventricular assist device (LVAD) outflow graft obstruction.
Incidence of acquired ventricular septal defect after transcatheter aortic valve replacement: A large single center experience
Paul Nona MD,Shazil Mahmood MD,Alejandro Lemor MD, MSc,Mohammed Qintar MD,Brian O'Neill MD,James Lee MD,Tiberio Frisoli MD,Dee Dee Wang MD,Marvin Eng MD,William W. O'Neill MD,Pedro A. Villablanca MD, MSc
doi : 10.1002/ccd.29897
Volume 98, Issue 5 p. 975-980
To determine the rate and clinical outcomes of post-TAVR VSD.
Causes and predictors of mortality after transcatheter mitral valve implantation in patients with severe mitral annulus calcification
Marina Urena MD, PhD,Thomas Lemann MD,Caroline Chong-Nguyen MD,Eric Brochet MD,Grégory Ducrocq MD, PhD,Jose-Luis Carrasco MD,Bernard Iung MD,Alec Vahanian MD,Dominique Himbert MD
doi : 10.1002/ccd.29874
Volume 98, Issue 5 p. 981-989
To evaluate the causes and predictors of mortality after valve-in-mitral annulus calcification (MAC) transcatheter mitral valve implantation (TMVI).
Edwards SAPIEN XT transcatheter pulmonary valve implantation: 5-year follow-up in a French Registry
Robin Le Ruz MD,Julien Plessis MD,Ali Houeijeh MD, PhD,Alban-Elouen Baruteau MD, PhD,Laurianne Le Gloan MD,Karine Warin Fresse MD,Clément Karsenty MD,Jérôme Petit MD,François Godart MD, PhD,Sébastien Hascoët MD, PhD,Patrice Guérin MD, PhD
doi : 10.1002/ccd.29862
Volume 98, Issue 5 p. 990-999
This study sought to investigate patient intermediate-term outcomes after transcatheter pulmonary valve replacement (TPVR) with Edwards SAPIEN valve.
Intracardiac echocardiographic-guided right-sided cardiac biopsy: Case series and literature review
Joseph L. Pearman MD,Stephen L. Wall MD,Lily Chen MD,Jason H. Rogers MD
doi : 10.1002/ccd.29302
Volume 98, Issue 5 p. 1000-1005
Endomyocardial biopsy (EMB) is a common procedure used to aid in the diagnosis of diffuse myocardial diseases and, less commonly, in the diagnosis of cardiac tumors. As cardiac tumors are often found in high-risk locations (ventricular free wall or atria), precision biopsy is paramount, and additional imaging, like transesophageal echocardiography is often required for guidance. The use of intracardiac echocardiography (ICE) to guide biopsy has been described, but there is no consensus on a standardized approach. We report our institutional approach with three cases of ICE-directed EMB performed with the 2.4?mm Jawz bioptome directed with an 8.5-Fr Agilis NxT steerable introducer. All cases were performed under guidance with the AcuNav ICE probe. There were no procedural complications and a definitive diagnosis was obtained in all three cases. We also review the available published cases of ICE-guided EMB in the literature–noting the different procedural approaches, complication rate, and diagnostic yield. There were only two negative biopsies reported among the published cases and no reported complications. Our review of all these cases suggests that ICE-guidance for EMB is superior to other forms of imaging in its ease of use and high definition of right-sided cardiac structures. We also feel that the use of the Agilis steerable sheath allows for more precise directing of the bioptome and is a critical component in performing a successful targeted biopsy.
Tricuspid clip implantation using the MitraClip system–A step-by-step guide
Ryan K. Kaple MD,Vratika Agarwal MD,Amir Azarbal MD,Lissa Sugeng MD, MPH,Gilbert H. L. Tang MD, MSc, MBA
doi : 10.1002/ccd.29796
Volume 98, Issue 5 p. 1006-1019
Many novel percutaneous interventions are being developed for application in the tricuspid valve position. At the present time, there are no commercially available devices for this application. There has been mounting evidence supporting the safety and efficacy of using the MitraClip system on the tricuspid valve. This review summarizes the peer reviewed data available to date supporting this procedure, outlines the step-by-step maneuvers using the MitraClip system for this application, and imaging techniques used prior to and during the procedure.
Hyperemic hemodynamic characteristics of serial coronary lesions assessed by pullback pressure gradients
Alessandro Candreva MD,Takuya Mizukami MD, PhD,Jeroen Sonck MD,Daniel Munhoz MD, PhD,Sakura Nagumo MD,Giuseppe Di Gioia MD,Emanuele Gallinoro MD,Niya Mileva MD,Jozef Bartunek MD, PhD,Eric Wyffels MD,Emanuele Barbato MD, PhD,Bernard De Bruyne MD, PhD,Divaka Perera MD,Carlos Collet MD, PhD
doi : 10.1002/ccd.29868
Volume 98, Issue 5 p. E647-E654
To characterize hemodynamics of serial coronary stenoses using fractional flow reserve (FFR) pullbacks and the pullback pressure gradients (PPG) index.
Long-term outcomes of patients with chronic inflammatory diseases after percutaneous coronary intervention
Erez Marcusohn MD,Robert Zukermann MD,Arthur Kerner MD,Ariel Roguin MD, PHD,Ofer Kobo MD
doi : 10.1002/ccd.29870
Volume 98, Issue 5 p. E655-E660
To assess the long-term outcomes of patients with chronic inflammatory diseases who underwent percutaneous coronary intervention (PCI).
One-year mortality in NSTEMI patients is unaffected by timing of PCI within the first week of admission: Results of a real-world cohort analysis
Nick D. Fagel MD,Giovanni Amoroso MD, PhD,Tanja Rabbering,Froukje Gescher,Maarten A. Vink MD, PhD,Ton Slagboom MD,René J. van der Schaaf MD, PhD,Jean-Paul R. Herrman MD, PhD,Mark S. Patterson MD, PhD,Nicola S. Vos MD, PhD,Eva C. Verbeek PhD,Robbert J. de Winter MD, PhD,Robert K. Riezebos MD, PhD
doi : 10.1002/ccd.29873
Volume 98, Issue 5 p. E661-E667
We aimed to explore the impact of time to percutaneous coronary intervention (PCI) (T2P) on 1-year mortality in non-ST-elevation myocardial infarction (NSTEMI) patients.
Viability and functional recovery after chronic total occlusion percutaneous coronary intervention
Stefan P. Schumacher MD,Henk Everaars MD,Wijnand J. Stuijfzand MD,Pepijn A. van Diemen MD,Roel S. Driessen MD,Michiel J. Bom MD,Ruben W. de Winter MD,Yvemarie B. O. Somsen MD,Jennifer W. Huynh BSc,Ramon B. van Loon MD, PhD,Peter M. van de Ven PhD,Albert C. van Rossum MD, PhD,Maksymilian P. Opolski MD, PhD,Alexander Nap MD, PhD,Paul Knaapen MD, PhD
doi : 10.1002/ccd.29888
Volume 98, Issue 5 p. E668-E676
This study evaluated myocardial viability as well as global and regional functional recovery after successful chronic coronary total occlusion (CTO) percutaneous coronary intervention (PCI) using sequential quantitative cardiac magnetic resonance (CMR) imaging.
Comparison of 6-month vascular healing response after bioresorbable polymer versus durable polymer drug-eluting stent implantation in patients with acute coronary syndromes: A randomized serial optical coherence tomography study
Masahiko Noguchi MD,Tomotaka Dohi MD, PhD,Shinya Okazaki MD,Mitsuaki Matsumura BS,Mitsuhiro Takeuchi MD,Hirohisa Endo MD, PhD,Yoshiteru Kato MD,Iwao Okai MD,Hiroki Nishiyama MD,Shinichiro Doi MD, PhD,Hiroshi Iwata MD, PhD,Kikuo Isoda MD, PhD,Eisuke Usui MD, PhD,Tatsuhiro Fujimura MD, PhD,Fumiyasu Seike MD, PhD,Gary S. Mintz MD,Katsumi Miyauchi MD,Hiroyuki Daida MD,Tohru Minamino MD, PhD,Akiko Maehara MD
doi : 10.1002/ccd.29892
Volume 98, Issue 5 p. E677-E686
This study was conducted to use optical coherence tomography (OCT) to compare vascular healing between bioresorbable polymer (BP) and durable polymer (DP) everolimus-eluting stents (EES) in patients with acute coronary syndromes (ACS).
Evaluation of a suspended radiation protection system to reduce operator exposure in cardiology interventional procedures
Federica Zanca PhD,Jérémie Dabin IR,Celine Collard DNP,Nicolas Alexandre IR,Alicia De Groote IR,Jean Paul Salembier MD,Michel Henry MD,Emmanuel Rombaut MD,Sonia Sghaier MD,Pierre-Emmanuel Massart MD
doi : 10.1002/ccd.29894
Volume 98, Issue 5 p. E687-E694
To investigate a novel suspended radiation shield (ZG), in reducing operator radiation exposure during cardiology interventions.
Utility of near-infrared spectroscopy to detect the extent of lipid core plaque leading to periprocedural myocardial infarction
Takaaki Matsuoka MD,Hideki Kitahara MD,Kan Saito MD,Naoto Mori MD,Kazuya Tateishi MD,Yoshihide Fujimoto MD,Yoshio Kobayashi MD
doi : 10.1002/ccd.29927
Volume 98, Issue 5 p. E695-E704
The aim of this study was to investigate whether lipid core plaque (LCP) in the entire stented segment detected by near-infrared spectroscopy-intravascular ultrasound (NIRS-IVUS) could predict procedural myocardial infarction (PMI) in patients undergoing percutaneous coronary artery intervention (PCI).
Ten-year outcomes of early generation sirolimus- versus paclitaxel-eluting stents in patients with left main coronary artery disease
Hanbit Park MD,Do-Yoon Kang MD,Seon Ok Kim MSc,Junghoon Lee MD,Ju Hyeon Kim MD,Junho Hyun MD,Pil Hyung Lee MD,Jung-Min Ahn MD,Seung-Jung Park MD,Duk-Woo Park MD,for the MAIN-COMPARE Investigators
doi : 10.1002/ccd.29930
Volume 98, Issue 5 p. E705-E714
To compare 10-year outcomes after implantation of sirolimus-eluting stents (SES) versus paclitaxel-eluting stents (PES) for left main coronary artery (LMCA) stenosis. Very long-term outcome data of patients with LMCA disease treated with drug-eluting stents (DES) have not been well described. In 10-year extended follow-up of the MAINCOMPARE registry, we evaluated 778 patients with unprotected LMCA stenosis who were treated with SES (n = 607) or PES (n = 171) between January 2000 and June 2006. The primary composite outcome (a composite of death, myocardial infarction [MI] or target-vessel revascularization [TVR]) was compared with an inverse-probability-of-treatment-weighting (IPTW) adjustment. Clinical events have linearly accumulated over 10?years. At 10?years, there were no significant differences between SES and PES in the observed rates of the primary composite outcome (42.0% vs. 47.4%; hazard ratio [HR] 0.85; 95% confidence interval [CI] 0.66–1.10), and definite stent thrombosis (ST) (1.9% vs. 1.8%; HR 1.02, 95% CI 0.28–3.64). In the IPTW-adjusted analyses, there were no significant differences between SES and PES in the risks for the primary composite outcome (HR 0.89, 95% CI 0.65–1.14) or definite ST (adjusted HR 1.05, 95% CI 0.29–3.90). In patients who underwent DES implantation, high overall adverse clinical event rates (with a linearly increasing event rate over time) were observed during extended follow-up. At 10?years, there were no measurable differences in outcomes between patients treated with SES vs. PES for LMCA disease. The incidence of stent thrombosis was quite low and comparable between the groups.
Hemodynamic changes during transcatheter atrial septal defect closure predict midterm heart failure deterioration in adults
Hiroyuki Yamamoto MD, PhD,Toshiro Shinke MD, PhD,Hiromasa Otake MD, PhD,Daisuke Terashita MD, PhD,Akira Nagasawa MD,Kousuke Tanimura MD,Kensuke Matsumoto MD, PhD,Hidekazu Tanaka MD, PhD,Ken-ichi Hirata MD, PhD
doi : 10.1002/ccd.29859
Volume 98, Issue 5 p. E715-E723
To investigate whether hemodynamic changes during balloon occlusion test (BOT) predict future heart failure (HF) deterioration after transcatheter atrial septal defect closure (tASD-closure).
Mid-term outcomes of the Pulsta transcatheter pulmonary valve for the native right ventricular outflow tract
Sang-Yun Lee MD, PhD,Gi Beom Kim MD, PhD,Seong-Ho Kim MD, PhD,So-Ick Jang MD,Jae Young Choi MD, PhD,I. Seok Kang MD, PhD,Young-Hwue Kim MD, PhD
doi : 10.1002/ccd.29865
Volume 98, Issue 5 p. E724-E732
The aim of this study is to present the mid-term outcomes of Pulsta valve.
Virtual support for remote proctoring in TAVR during COVID-19
Fatih Arslan MD, PhD, FESC,Ulrich Gerckens MD
doi : 10.1002/ccd.29504
Volume 98, Issue 5 p. E733-E736
The current report describes a single operator's experience of the first use of smartglass technology as a facilitator of virtual support during TAVR proctoring.
Vascular complications with a plug-based vascular closure device after transcatheter aortic valve replacement: Predictors and bail-outs
Maarten P. van Wiechen MD,Herbert Kroon MD,Thijmen W. Hokken MD,Joris F. Ooms MD,Marjo J. de Ronde-Tillmans,Joost Daemen MD, PhD,Peter P. de Jaegere MD, PhD,Nicolas M. Van Mieghem MD, PhD
doi : 10.1002/ccd.29506
Volume 98, Issue 5 p. E737-E745
The MANTA vascular closure device (VCD) is dedicated to large bore access closure and associated with favorable results in selected study populations. Anatomical predictors for access site complications are lacking.
Balloon versus self-expandable transcatheter aortic valve implantation for bicuspid aortic valve stenosis: A meta-analysis of observational studies
Michel Pompeu B.O. Sá MD, MSc, PhD,Matheus Simonato MD,Jef Van den Eynde BSc,Luiz Rafael P. Cavalcanti MD,Ali Alsagheir MBBS, MSc,Aspasia Tzani MD, PhD,Luca Nai Fovino MD, PhD,Polydoros N. Kampaktsis MD, MSc,Michele Gallo MD,Pietro L. Laforgia MD,Arjang Ruhparwar MD, PhD, ChM,Alexander Weymann MD, MHBA, PhD, FEBCTS, FESC,Sameer A. Hirji MD, MPH,Tsuyoshi Kaneko MD,Gilbert H. L. Tang MD, MSc, MBA, FRCSC, FACC
doi : 10.1002/ccd.29538
Volume 98, Issue 5 p. E746-E757
There is a rising trend for transcatheter aortic valve implantation (TAVI) in bicuspid aortic stenosis patients. Data on the use of self-expandable (SEV) vs. balloon-expandable (BEV) valves in these patients are scarce. Therefore, we systematically compared clinical outcomes in bicuspid aortic stenosis patients treated with SEV and BEV.
Prognostic implication of right ventricular dysfunction and tricuspid regurgitation following transcatheter aortic valve replacement
Yoav Granot MD,Ilan Merdler MD,Ariel Finkelstein MD,Yaron Arbel MD,Shmuel Banai MD,Yan Topilsky MD,Lorin Arie Scwartz MD,Amit Segev MD,Israel Barbash MD,Paul Fefer MD,Haim Danenberg MD,Mony Shuvy MD,Gidon Perlman MD,Ran Kornowski MD,Yaron Shapira MD,Katia Orvin MD,Arie Steinvil MD
doi : 10.1002/ccd.29639
Volume 98, Issue 5 p. E758-E767
Right ventricular (RV) dysfunction and tricuspid regurgitation (TR) are associated with adverse outcomes in severe aortic stenosis (AS) patients. Our aim was to evaluate the association between ?moderate TR and RV dysfunction on long-term mortality following transcatheter aortic valve replacement (TAVR).
Heart valve sizing and clinical outcomes in patients undergoing transcatheter aortic valve implantation
Taishi Okuno MD,Dik Heg PhD,Jonas Lanz MD, MSc,Fabien Praz MD,Christoph Gräni MD,Bettina Langhammer MD,David Reineke MD,Lorenz Räber MD, PhD,Peter Wenaweser MD,Thomas Pilgrim MD,Stephan Windecker MD,Stefan Stortecky MD
doi : 10.1002/ccd.29700
Volume 98, Issue 5 p. E768-E779
To investigate the impact of transcatheter heart valve (THV) sizing on procedural results and clinical outcomes following transcatheter aortic valve implantation (TAVI).
Fusion imaging guided implantation of a Tricento transcatheter heart valve for severe tricuspid regurgitation
Niklas F. Boeder MD,Matthias Bayer MD,Oliver Dörr MD,Holger M. Nef MD
doi : 10.1002/ccd.29587
Volume 98, Issue 5 p. E780-E784
We report the case of a 64-year-old patient with history of chronic kidney disease on dialysis who was repeatedly hospitalized due to hydropic decompensation. Right heart failure with secondary severe tricuspid regurgitation was diagnosed. An interventional approach was recommended due to the heavy calcification of the sinus venosus and the perioperative risk (EuroScore II 3.2%) and taking into account the explicit request of the patient. After analysis of a full-cycle computed tomography, the patient was eligible for the implantation of the Tricento transcatheter heart valve. The custom-made prosthesis was implanted successfully using periprocedural transoesophageal guidance supported by fusion imaging that integrates live co-registration. After implantation of the valve prosthesis, the primary result was excellent. The patient was discharged without further complications shortly after the procedure and her status is being closely monitored.
